Bank of America’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bank of America’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-75,000	Closed	-$5.19M	–	8478
2024 Q1	$5.19M	Buy	+75,000	New	+$5.15M	﹤0.01%	3575
2019 Q4	–	Sell	-60,000	Closed	-$448K	–	7478
2019 Q3	$448K	Buy	60,000 +39,100	+187%	+$375K	﹤0.01%	5160
2019 Q2	$271K	Buy	+20,900	New	+$268K	﹤0.01%	5460
2019 Q1	–	Sell	-246,900	Closed	-$2.81M	–	7472
2018 Q4	$2.81M	Sell	246,900 -6,500	-3%	-$105K	﹤0.01%	3558
2018 Q3	$5.5M	Hold	253,400	–	–	﹤0.01%	3094
2018 Q2	$4.48M	Buy	253,400 +180,000	+245%	+$3.65M	﹤0.01%	3262
2018 Q1	$1.54M	Buy	+73,400	New	+$1.43M	﹤0.01%	4074
2016 Q4	–	Sell	-50,400	Closed	-$768K	–	7370
2016 Q3	$768K	Buy	+50,400	New	+$2.04M	﹤0.01%	4340

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bank of America's ITCI Position: Q2 2025 in Review

Bank of America sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,815,287 shares — an estimated $239M sold.

Bank of America first reported a position in ITCI in Q2 2014 and held it in 42 quarters. The position peaked at $239M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Bank of America reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Bank of America sold 1,815,287 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $239M.
Bank of America first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 42 quarters.
Bank of America's Intra-Cellular Therapies Inc. position peaked at $239M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Bank of America's 13F filing for Q2 2025, filed 14 Aug 2025.